NCT00267020View on ClinicalTrials.gov

Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Pancreatic Neoplasm
Interventions
DRUG

enzastaurin

1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles

DRUG

gemcitabine

1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00267020 - Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter